Log in
ASX:MVP

Medical Developments International Limited (MVP.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$7.63
MA: A$7.63▼
A$7.63
52-Week Range N/A
Volume169,499 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend Yield0.62%
BetaN/A
Medical Developments International Limited manufactures and distributes pharmaceutical and veterinary products, and medical devices. The company operates through three segments: Pharmaceuticals, Medical Devices, and Veterinary Products. It offers asthma and COPD pressurized metered dose inhalers, as well as masks and peak flow meters for asthma management for use in home or in hospitals; Penthrox, a prescription only medicine for pain relief; medical devices; and various veterinary anesthetic machines to veterinarians. The company operates in Australia, New Zealand, the United Kingdom, rest of Europe, Canada, the Middle East, Asia, South Africa, North America, and internationally. Medical Developments International Limited was incorporated in 2003 and is headquartered in Scoresby, Australia.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.83 out of 5 stars


Industry, Sector and Symbol

Stock Exchange ASX
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
Current SymbolASX:MVP
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.medicaldev.com
Phone61 3 9547 1888
EmployeesN/A

Debt

Debt-to-Equity Ratio7.74
Current Ratio3.16
Quick Ratio2.39

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$22.54 million
Price / Sales0.00
Cash FlowN/A
Price / Cash Flow21.37
Book ValueA$0.66 per share
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive MVP News and Ratings via Email

Sign-up to receive the latest news and ratings for MVP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Medical Developments International Limited (MVP.AX) (ASX:MVP) Frequently Asked Questions

What stocks does MarketBeat like better than Medical Developments International Limited (MVP.AX)?

Wall Street analysts have given Medical Developments International Limited (MVP.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Medical Developments International Limited (MVP.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How often does Medical Developments International Limited (MVP.AX) pay dividends? What is the dividend yield for Medical Developments International Limited (MVP.AX)?

Medical Developments International Limited (MVP.AX) declared a Interim dividend on Thursday, February 20th. Shareholders of record on Friday, April 17th will be given a dividend of 0.02 per share on Friday, April 17th. This represents a yield of 0.18%. The ex-dividend date of this dividend is Thursday, March 5th.
View Medical Developments International Limited (MVP.AX)'s dividend history.

Who are some of Medical Developments International Limited (MVP.AX)'s key competitors?

Some companies that are related to Medical Developments International Limited (MVP.AX) include Antisense Therapeutics Limited (ANP.AX) (ANP), Bayer Aktiengesellschaft (BAYN.F) (BAYN), Mayne Pharma Group (MAYNF), Mayne Pharma Group Limited (MYX.AX) (MYX), Opthea Limited (OPT.AX) (OPT), Otsuka (OTSKY), Patrys Limited (PAB.AX) (PAB), Pharmaxis Ltd (PXS.AX) (PXS), Recce Pharmaceuticals Ltd (RCE.AX) (RCE), Roche (RHHVF), Sanofi (SAN.PA) (SAN), Sinclair Pharma plc (SPH.L) (SPH) and Vita Life Sciences Limited (VLS.AX) (VLS).
View all competitors.

What other stocks do shareholders of Medical Developments International Limited (MVP.AX) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medical Developments International Limited (MVP.AX) investors own include Talon Petroleum Limited (TPD.AX) (TPD), Mesoblast (MESO), Gold Road Resources Limited (GOR.AX) (GOR), Elixinol Global (ELLXF), Core Lithium Ltd (CXO.AX) (CXO) and Bubs Australia Limited (BUB.AX) (BUB).

Who are Medical Developments International Limited (MVP.AX)'s key executives?

Medical Developments International Limited (MVP.AX)'s management team includes the following people:
  • Mr. Mark Edwards C.A., BAcc, CA, CFO & Company Sec.
  • Mr. Brent MacGregor, Chief Exec. Officer
  • Matthew Cramer, Chief of Operations & Supply Chain
  • Thomas Materia, Head of Sales & Marketing
  • Tara Collier, Head of HR
  • Dr. Scott Courtney, Chief Scientific Officer
  • Michelle Bradney, Head of Medical Affairs
  • Wai Ng Chi, Head of Regulatory Affairs
  • Neil Issa, Head of Quality
  • Wayne Pearce, Head of Production

What is Medical Developments International Limited (MVP.AX)'s stock symbol?

Medical Developments International Limited (MVP.AX) trades on the ASX under the ticker symbol "MVP."

How big of a company is Medical Developments International Limited (MVP.AX)?

Medical Developments International Limited (MVP.AX) has a market capitalization of $0.00 and generates $22.54 million in revenue each year. Medical Developments International Limited (MVP.AX) employs 65 workers across the globe.

What is Medical Developments International Limited (MVP.AX)'s official website?

The official website for Medical Developments International Limited (MVP.AX) is www.medicaldev.com.

How can I contact Medical Developments International Limited (MVP.AX)?

The company can be reached via phone at 61 3 9547 1888.

This page was last updated on 11/29/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.